GUY L. REED, MD
Osteopathic Medicine at Union Ave, Memphis, TN
License number
Tennessee 43969
Category
Osteopathic Medicine
Type
Cardiovascular Disease
License number
Tennessee 054923
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
1407 Union Ave SUITE 200, Memphis, TN 38104
Phone
(901) 866-8813
(901) 302-2120 (Fax)
(901) 866-8373
(901) 302-2360 (Fax)
(901) 302-2120 (Fax)
(901) 866-8373
(901) 302-2360 (Fax)
Personal information
See more information about GUY L. REED at radaris.comName
Address
Phone
5787 Richardson Landing Rd, Drummonds, TN 38023
1840 Overton Park Ave, Memphis, TN 38112
126 Grandview Cir, Old Hickory, TN 37138
129 Pinecrest Rd, Kingsport, TN 37660
2531 Edinburgh St, Old Hickory, TN 37138
Professional information
See more information about GUY L. REED at trustoria.com
Guy L Reed, Memphis TN
Guy L Reed, Memphis TN
Specialties:
Internal Medicine, Cardiovascular Disease, Cardiology
Work:
UT Medical Group
1265 Union Ave, Memphis, TN 38104 Utmg Cardiology
956 Court St #D334, Memphis, TN 38103 UT Medical Group
877 Jefferson Ave, Memphis, TN 38103 University of Tennessee
956 Court Ave, Memphis, TN 38103
1265 Union Ave, Memphis, TN 38104 Utmg Cardiology
956 Court St #D334, Memphis, TN 38103 UT Medical Group
877 Jefferson Ave, Memphis, TN 38103 University of Tennessee
956 Court Ave, Memphis, TN 38103
Education:
Stanford University (1981)
Method Of Increasing Plasmin Activity Through Antiplasmin Conversion
Method Of Increasing Plasmin Activity Through Antiplasmin Conversion
US Patent:
2010008, Apr 8, 2010
Filed:
Apr 25, 2008
Appl. No.:
12/597311
Inventors:
Guy L. Reed - Memphis TN, US
International Classification:
A61K 38/48, A61K 38/46, G01N 33/573, A61K 31/727, A61K 31/60
US Classification:
424 9464, 424 946, 435 74, 514 56, 514165
Abstract:
Methods for increasing plasmin activity in a patient in need thereof are provided, comprising administering to the patient a therapeutic amount of an agent which binds to α2-antiplasmin at a binding site to increase conversion of cc2-antiplasmin from an inhibitor to a plasmin substrate, thereby increasing plasmin activity in the patient. Also provided are methods for the identification of compounds or molecules that increase plasmin activity, comprising determining whether the compound or molecule binds to a binding site on α2-antiplasmin which increases the conversion of α2-antiplasmin from an inhibitor to a plasmin substrate, wherein the compound or molecule is not an antibody, thereby identifying a compound or molecule which increases plasmin activity. Further provided are pharmaceutical compositions and methods of use thereof for the treatment of myocardial infarction, thrombosis, ischemic stroke, and pulmonary embolism.